Company Description
Generate Biomedicines is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development.
Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health.
Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies.
We have built our Generate Platform to be a tight and fully-integrated loop (design–build–test–learn) to create proprietary, therapeutically relevant data and differentiated molecular solutions for the biological challenges we aim to address.
In addressing these challenges, the Generate Platform can engineer solutions against therapeutic targets by either starting from existing reference proteins or suggesting completely novel ones without a reference starting point, also known as de novo design.
The Generate Platform’s therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin (“TSLP”) monoclonal antibody, which is enrolling patients in pivotal Phase 3 clinical trials for severe asthma.
The first patient was dosed in one of the Phase 3 clinical trials on January 26, 2026. We also expect to advance two additional computationally generated oncology product candidates into Phase 1 clinical trials in 2026.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 312 |
| CEO | Michael Nally |
Contact Details
Address: 101 South Street, Suite 900 Somerville, MA 02143 United States | |
| Phone | (888) 469-0055 |
| Website | generatebiomedicines.com |
Stock Details
| Ticker Symbol | GENB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2100782 |
| Employer ID | 83-1630228 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Nally, M.B.A. | Chief Executive Officer and Director |
| Gevorg Grigoryan, Ph.D. | Co-Founder and Chief Technology Officer |
| Beth Grous | Chief People Officer |
| Aarif Khakoo, M.D., M.B.A. | Chief Scientific Officer |
| Laurie Lee, M.D. | Chief Medical Officer |
| Sean Martin, J.D. | Chief Legal Officer and General Counsel |
| Jason Silvers, M.D., J.D. | President and Chief Financial Officer |
| Noubar B. Afeyan, Ph.D. | Chairperson of the Board |
| Frances Arnold, Ph.D. | Director |
| Stéphane Bancel, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 4, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 23, 2025 | DRS | [Cover] Draft Registration Statement |